Quantcast
Last updated on April 23, 2014 at 17:36 EDT

Latest Melatonin receptor agonist Stories

2013-11-15 00:22:01

HETLIOZ(TM) is the First Potential Treatment to be Reviewed by the FDA for Non-24 WASHINGTON, Nov. 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (Advisory Committee) voted overwhelmingly to recommend the approval of Vanda's New Drug Application (NDA) for tasimelteon, proposed tradename HETLIOZ(TM), for the treatment of Non-24-Hour...

2013-07-29 20:21:11

WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing and granted a priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. The FDA grants priority review status for a "drug that treats a serious condition and, if approved, would...